Home › Myelofibrosis › Washington
Myelofibrosis clinical trials in Washington, DC
4 studies for Myelofibrosis are looking for participants at sites in and around Washington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
RecruitingPhase 3
- American Oncology Partners PA Center for Cancer and Blood Disorders, Bethesda · 7 mi away
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
RecruitingPhase 3
- MedStar Georgetown University Hospital, Washington D.C.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Silver Spring · 7 mi away
- Massive Bio SYNERGY-AI site, Bethesda · 7 mi away
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
RecruitingPhase 3
- MedStar Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington D.C.
- The Center for Cancer and Blood Disorders, Bethesda · 7 mi away
Myelofibrosis trials in other cities
- Houston, TX19 studies
- New York City, NY18 studies
- Boston, MA12 studies
- Durham, NC12 studies
- Columbus, OH11 studies
- Seattle, WA11 studies
- Salt Lake City, UT10 studies
- Miami, FL10 studies
- Nashville, TN9 studies
- Baldwin Park, CA9 studies
- Atlanta, GA9 studies
- Tampa, FL9 studies
Other studies in Washington
- Cancer (all types)58 studies
- Non-Small Cell Lung Cancer55 studies
- Breast Cancer46 studies
- Metastatic Cancer43 studies
- Lung Cancer41 studies
- Prostate Cancer38 studies
- Obesity33 studies
- Colorectal Cancer29 studies
- Cardiovascular Disease28 studies
- Bladder Cancer26 studies
- Acute Myeloid Leukemia24 studies
- Ovarian Cancer23 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.